SPOTLIGHT: New HIV drugs lower virus levels


Early-stage clinical trials show that maraviroc, Pfizer's foray into a new class of anti-HIV drugs, significantly decreased levels of the virus in asymptomatic HIV-positive patients, according to data presented today at the 3rd International AIDS Society Conference. Release

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.